Johnson & Johnson (JNJ) 108.16 $JNJ
Final Glance: Pharmaceuticals companies
AP - 1 hr 13 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)
Final Glance: Medical Devices companies
AP - 1 hr 13 mins ago
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 17 mins ago
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 305.43 (-12.55), JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45), AFFX: 9.71 (+0.02)
Halliburton and Geron are big market movers
AP - 2 hrs 47 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 39.80 (-2.05), AMZN: 327.82 (+11.34), JNJ: 108.16 (-0.91), HTZ: 21.69 (-1.04), GERN: 2.76 (+0.45), HAL: 55.08 (+1.29), JWN: 74.17 (+0.92), NOK: 7.86 (-0.40), BHI: 59.89 (+1.14)
Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.11 (+1.15), BIIB: 305.43 (-12.55), JNJ: 108.16 (-0.91), ACT: 243.77 (+2.14)
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 39.80 (-2.05), JNJ: 108.16 (-0.91), HTZ: 21.69 (-1.04), VA: 30.00 (+30.00), GERN: 2.76 (+0.45), JWN: 74.17 (+0.92)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)
Midday Glance: Medical Devices companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)
Early Glance: Medical Devices companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)
Early Glance: Pharmaceuticals companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)
Setting Up A Portfolio That Millennials Can Relate To
FinancialDave - at Seeking Alpha - Fri Nov 14, 9:05AM CST
JNJ: 108.16 (-0.91), VTV: 83.79 (+0.02), SPY: 204.24 (+0.05)
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 108.16 (-0.91), EW: 124.50 (-0.05)
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.16 (-0.91), ABT: 43.81 (-0.78), DHR: 82.23 (-0.17), MR: 31.06 (-0.16)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), MRK: 59.07 (-0.47), ABBV: 64.00 (+0.37)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.16 (-0.91), PFE: 30.34 (-0.08), ABBV: 64.00 (+0.37)
ADHD drug hits FDA trouble
at Investor's Business Daily - Thu Nov 13, 5:37PM CST
Drugmaker Mallinckrodt (MNK) said that the FDA is no longer recognizing its generic ADHD drug, methylphenidate ER, as an equivalent to Johnson & Johnson's (JNJ) Concerta and is reclassifying the treatment as "therapeutically inequivalent."...
MNK: 88.11 (+1.15), JNJ: 108.16 (-0.91)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45)
Final Glance: Pharmaceuticals companies
AP - 1 hr 13 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)
Final Glance: Medical Devices companies
AP - 1 hr 13 mins ago
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 17 mins ago
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 305.43 (-12.55), JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45), AFFX: 9.71 (+0.02)
Halliburton and Geron are big market movers
AP - 2 hrs 47 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 39.80 (-2.05), AMZN: 327.82 (+11.34), JNJ: 108.16 (-0.91), HTZ: 21.69 (-1.04), GERN: 2.76 (+0.45), HAL: 55.08 (+1.29), JWN: 74.17 (+0.92), NOK: 7.86 (-0.40), BHI: 59.89 (+1.14)
Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.11 (+1.15), BIIB: 305.43 (-12.55), JNJ: 108.16 (-0.91), ACT: 243.77 (+2.14)
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 39.80 (-2.05), JNJ: 108.16 (-0.91), HTZ: 21.69 (-1.04), VA: 30.00 (+30.00), GERN: 2.76 (+0.45), JWN: 74.17 (+0.92)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)
Midday Glance: Medical Devices companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)
Early Glance: Medical Devices companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)
Early Glance: Pharmaceuticals companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)
Setting Up A Portfolio That Millennials Can Relate To
FinancialDave - at Seeking Alpha - Fri Nov 14, 9:05AM CST
JNJ: 108.16 (-0.91), VTV: 83.79 (+0.02), SPY: 204.24 (+0.05)
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 108.16 (-0.91), EW: 124.50 (-0.05)
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.16 (-0.91), ABT: 43.81 (-0.78), DHR: 82.23 (-0.17), MR: 31.06 (-0.16)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), MRK: 59.07 (-0.47), ABBV: 64.00 (+0.37)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.16 (-0.91), PFE: 30.34 (-0.08), ABBV: 64.00 (+0.37)
ADHD drug hits FDA trouble
at Investor's Business Daily - Thu Nov 13, 5:37PM CST
Drugmaker Mallinckrodt (MNK) said that the FDA is no longer recognizing its generic ADHD drug, methylphenidate ER, as an equivalent to Johnson & Johnson's (JNJ) Concerta and is reclassifying the treatment as "therapeutically inequivalent."...
MNK: 88.11 (+1.15), JNJ: 108.16 (-0.91)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45)
